


# LuCID Clinical Trial

## Early Detection of Lung Cancer

THIS YEAR  
**LUNG  
CANCER**  
WILL COST THE  
**NHS** NATIONAL  
HEALTH  
SERVICE  
**£2.5  
Billion**

THIS YEAR  
**44,000**  
PEOPLE WILL BE  
**DIAGNOSED** WITH  
**LUNG CANCER** AND  
**35,200**  
WILL DIE IN THE **UK**



UNFORTUNATELY  
**ONLY**



OF

**PATIENTS**



ARE DETECTED AT STAGE I

THERE IS AN **URGENT** AND **GROWING** NEED  
**TO IMPROVE EARLY DIAGNOSIS**  
IN **LUNG CANCER**




EVERY TIME WE **BREATHE** OUT  
THERE OVER **A THOUSAND** OF  
**CHEMICALS** ON OUR BREATH

SOME OF THESE CHEMICALS ARE  
'TELL TALE' MARKERS OF **DISEASE**



"**OWLSTONE MEDICAL** HAS DEVELOPED THE **BREATH BIOPSY PLATFORM**  
WHICH ENABLES RELIABLE COLLECTION AND ANALYSIS OF **VOLATILE  
ORGANIC COMPOUNDS** IN BREATH"



THE **BREATH BIOPSY  
PLATFORM** IS BEING USED IN  
THE **WORLD'S** LARGEST BREATH-  
BASED **CLINICAL TRIALS**

THE **LuCID** TRIAL WILL RECRUIT UP TO  
**4,000** PATIENTS ACROSS MULTIPLE  
CLINICAL SITES IN **EUROPE**, AND IS  
EVALUATING THE UTILITY OF **BREATH  
BIOMARKERS** IN DETECTION OF  
**LUNG CANCER**

**QUICK, NON-INVASIVE** AND **EASY TO USE**,  
IT CAN BE USED IN A DOCTOR'S OFFICE  
TO HELP DETERMINE IF **HIGH RISK**  
**PATIENTS** SHOULD BE **REFERRED** FOR  
TESTING IN **HOSPITAL**



TO SAVE

**100,000**  
LIVES


OUR  
**MISSION**



AND SAVE

\$ **1.5** BILLION  
HEALTHCARE COSTS


# The LuCID Trial




**PATIENTS** WITH SUSPECTED LUNG CANCER GIVE A SAMPLE **AT THE SAME TIME** AS THEIR HOSPITAL APPOINTMENT



ALL PATIENTS HAVE TO DO IS **BREATHE THROUGH THE ReCIVA BREATH SAMPLER FOR 10 MINUTES**




**DATA ANALYSIS**  
WITH OWLSTONE MEDICAL'S  
**MACHINE LEARNING**  
ALGORITHMS AND BREATH BIOPSY  
DIGITAL BIOBANK



BREATH BIOPSY  
SAMPLES ARE SENT FOR  
**ANALYSIS**  
IN OWLSTONE MEDICAL'S  
**BREATH BIOPSY LAB**

## How Does Breath Biopsy Work?



## SCREENING



THE CHEMICAL MARKERS OF LUNG CANCER ARE PRESENT EVEN IN THE EARLIEST STAGES OF THE DISEASE. FOR THE FIRST TIME THERE IS THE REAL POTENTIAL FOR ROUTINE SCREENING AND IMPROVED RATES OF EARLY DIAGNOSIS, TRANSFORMING THE LIVES OF COUNTLESS PATIENTS AND THEIR FAMILIES.



[owlstonemedical.com/lucid](https://owlstonemedical.com/lucid)

Owlstone Medical Ltd, 183 Cambridge Science Park, Milton Road, Cambridge, CB4 0GJ, UK  
Company Number 04955647 | VAT Number 260449214

Owlstone Medical's Products and Services are for research use only.  
Not for use in diagnostic procedures.

